Christopher J. Kirk
9Patents
2h-index
23Co-inventors
47Inventor score
Filing activity: Nov 11, 2010 → Sep 23, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8853147B2 | Use of peptide epoxyketones for metastasis suppression | Human Necessities | 8 | Active |
| US9511109B2 | Combination therapy with peptide epoxyketones | Human Necessities | 5 | Active |
| US10022326B2 | Liposomal compositions of epoxyketone-based proteasome inhibitors | Human Necessities | 2 | Active |
| USRE47954E1 | Combination therapy with peptide epoxyketones | General | 0 | Active |
| US10596222B2 | Combination therapy with peptide epoxyketones | Human Necessities | 0 | Active |
| US12076363B2 | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US9295708B2 | Modified release formulations for oprozomib | Human Necessities | 0 | Active |
| US10662479B2 | Immunoglobulin expression levels as biomarker for proteasome inhibitor response | General | 0 | Revoked |
| US10870889B2 | Immunoglobulin expression levels as biomarker for proteasome inhibitor response | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.